EPLERENONE IN THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY
Published 2022
- 26th ESCRS Winter Meeting
Reference: P234
| Type: Abstracts
| DOI:
10.82333/a0dv-md56
Authors:
Ismail Essamlali* 1
, mohamed cherif khalifi 1
, manal yousfi 1
, hammoumi zineb 1
, loubna el maaloum 1
, bouchra allali 1
, asmaa el kettani 1
1pediatric ophthalmology,20 august hospital , casablanca,casablanca,Morocco
Purpose
Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment (DSR) usually located at the posterior pole, associated with changes in the pigment epithelium it is characterized by a vanishing point causing sub-retinal fluid accumulation.
Setting
We report a case of a patient with chronic central serous chorioretinitis evolving for about three months , who has positively responded to a medication
Methods
Eprenolone 25 mg was given per day the first week, then 50 mg per day for an average treatment duration of 12 weeks) . The patient was seen a month later, with visual acuity recovery from 3/10 to 10/10, with improvement in macular syndrome
Results
CRSC is a rare complication of systemic corticosteroid therapy, several cases of corticosteroid-induced CRSC were found in the literature , It has been suggested that CRSC may result from hyperactivation of mineralocorticoid receptors in choroidal vessels, and thus it has been hypothesized that mineralocorticoid receptor antagonists may be a treatment for CRSC
Different studies where conducted to show the effect of eprenolone in this pathology , a dose of 25–50 mg/day has been found to be effective and well-tolerated for the treatment of chronic CSCR. Treatment with mineralocorticoid receptor antagonists appears to be a promising therapeutic option
Conclusion
CSCR is a challenging disease to understand and treat, since its pathogenesis remains elusive and multifactorial. Pharmacologic approaches, like eplerenone, are intriguing, as they target several pathophysiological pathways and may lead to visual acuity improvement and more rapid recovery.